Biogen Boosts FY21 Adj. EPS Outlook; Q1 Results Top Estimates - Quick Facts

While reporting financial results for the first quarter on Thursday, Biogen Inc. (BIIB) raised its adjusted earnings guidance for the full-year 2021, but maintained revenue outlook.

For fiscal 2021, the company raised its adjusted earnings guidance to a range of $17.50 to $19.00 per share from the range of $17.00 to $18.50 per share, but maintained its revenues outlook between $10.45 billion and $10.75 billion.

On average, 30 analysts polled by Thomson Reuters expect the company to report earnings of $18.41 per share on revenues of $10.57 billion for the year. Analysts' estimates typically exclude special items.

For the first quarter, the company reported net income attributable to the company of $410.2 million or $2.69 per share, sharply down from $1.40 billion or $8.08 per share in the prior-year quarter. Excluding items, adjusted earnings for the quarter were $5.34 per share, compared to $9.14 per share in the year-ago quarter.

Total revenue for the quarter declined to $2.69 billion from $3.53 billion in the same quarter last year.

The Street expected the company to report earnings of $5.04 per share on revenues of $2.65 billion for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hedge-fund billionaire William Ackman's Pershing Square Tontine Holdings Ltd. (PSTH) agreed to acquire 10% of Universal Music Group from French media conglomerate Vivendi (VIV.L, VIVEF.PK) for about $4 billion, the companies said in a statement on Sunday. The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings.
Follow RTT